<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42048">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150824</url>
  </required_header>
  <id_info>
    <org_study_id>1307.4</org_study_id>
    <secondary_id>2013-003646-16</secondary_id>
    <nct_id>NCT02150824</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Three BI 187004 Doses Given Once Daily as Mono-therapy and of the Highest BI 187004 Dose Given Once Daily as Add on Treatment to Metformin Over 28 Days in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and tolerability of once daily oral doses of BI 187004 in patients with
      type 2 diabetes mellitus without oral antidiabetic treatment and in patients on a stable
      metformin background treatment over 28 days. Assess the effect on fasting plasma glucose
      after 28 days of treatment and to investigate the pharmacokinetics and pharmacodynamics of
      BI 187004.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The percentage of patients with drug- related adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment</measure>
    <time_frame>baseline and 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 187004 low dose mono QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet containing low dose of BI 187004 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 medium dose mono QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 high dose mono QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet containing high dose of BI 187004 or matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 187004 high dose QD add on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BI 187004 high dose matching placebo once daily</description>
    <arm_group_label>BI 187004 high dose mono QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BI 187004 medium dose matching placebo once daily</description>
    <arm_group_label>BI 187004 medium dose mono QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BI 187004 high dose matching placebo once daily add on to background metformin</description>
    <arm_group_label>BI 187004 high dose QD add on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004 high dose once daily add on to background metformin</description>
    <arm_group_label>BI 187004 high dose QD add on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BI 187004 low dose matching placebo once daily</description>
    <arm_group_label>BI 187004 low dose mono QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004 medium dose once daily</description>
    <arm_group_label>BI 187004 medium dose mono QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004 low dose once daily</description>
    <arm_group_label>BI 187004 low dose mono QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 187004</intervention_name>
    <description>BI 187004 high dose once daily</description>
    <arm_group_label>BI 187004 high dose mono QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male or postmenopausal or hysterectomised female patients with diagnosis of Type 2
             Diabetes Mellitus (T2DM) before informed consent

          2. To be eligible for Arm 1

               1. Oral antidiabetic mono-therapy for the last 12 weeks prior to Informed Consent
                  AND Glycosylated haemoglobin (HbA1c) &gt;= 6.5% and &lt;= 8.5% at Visit 1a

               2. Therapy-naïve patients or no antidiabetic treatment within 4 weeks prior to
                  Informed Consent AND HbA1c &gt;= 7.0% and &lt;= 9.5% at Visit 1a.

          3. To be eligible for Arm 2:

             a. Antidiabetic treatment with metformin with an unchanged daily dose for 12 weeks
             prior to Informed Consent AND patient´s willingness to keep this therapy stable
             during the course of the trial AND HbA1c &gt;= 7.0% and &lt;= 9.5% at Visit 1a

          4. Age &gt;=18 and &lt;=80 years for female hysterectomised and male patients at Visit 1a

          5. Age &gt;=55 and &lt;=80 years for female postmenopausal (defined by the absence of menses
             for at least 2 years) patients  at Visit 1a

          6. Body mass index (BMI) &gt;= 28 and &lt;= 40 kg/m2 at Visit 1a

          7. Signed and dated written informed consent prior to admission to the study in
             accordance with Good Clinical Practice (GCP) and the local legislation

        Exclusion criteria:

          1. Treatment with a non-oral antidiabetic therapy or with more than one oral
             antidiabetic medication within 12 weeks prior to visit 1a.

          2. Fasted plasma glucose &gt; 270 mg/dl (&gt;15.0 mmol/l) on two consecutive days after
             screening (Visit 1a) confirmed by a fasted laboratory blood glucose test until first
             administration of the trial drug

          3. Any laboratory value more than 3 times above upper limit normal (ULN) at screening
             (visit 1a) or any other laboratory value outside the reference range and clinically
             relevant in the investigator judgment

          4. Any known clinically relevant concomitant diseases or chronic diseases other than
             type 2 diabetes, hyperlipidaemia or medically treated hypertension

          5. Medical history of cancer or treatment for cancer in the last five years prior to the
             Visit 1a.

          6. History of Cushing syndrome, Addison´s disease, congenital adrenal hyperplasia or
             polycystic ovary syndrome

          7. Treatment with systemic, inhalatory or ophthalmologic steroids within 12 weeks prior
             to first administration of the trial drug.

          8. Treatment compliance during the run-in period is outside the per protocol range
             defined range, between 80%-120% treatment compliance.

          9. Use of any other concomitant medication within 5 half-lives before the first
             administration of the trial drug except for allowed co-medication.

         10. Surgery or trauma with significant blood loss (more than 500 ml) within the last 3
             months prior to informed consent or blood donation (more than 100 ml) within four
             weeks prior to first administration of study medication or planned during the trial

         11. Any other medical condition that would interfere with trial participation based on
             investigator´s judgement or any on-going clinical condition that would jeopardize
             patient´s or site personnel´s safety or study compliance based on investigator
             judgement. Smoking habits interfering with hospitalization. Patients not willing to
             abstain from alcoholic beverages during inpatient visits

         12. Male patients not willing to use adequate contraception (sexual abstinence, condom
             use plus another form of contraception e.g. spermicide, oral contraceptive taken by
             female partner, sterilisation, intrauterine device) during the whole study period
             from the time of the first intake of study drug until three months after the last
             intake
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1307.4.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1307.4.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>1307.4.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
